As part of the ongoing safety investigation of potentially carcinogenic impurities detected in angiotensin II receptor blocker (ARB) medications, the Food and Drug Administration (FDA) has released a ...

An immediately effective guidance from the US Food and Drug Administration (FDA) details steps to be taken to detect and prevent the introduction of potentially carcinogenic nitrosamine impurities ...

Nitrosamines have become a significant concern in the pharmaceutical industry due to their potential carcinogenic risks. Regulatory agencies such as the FDA, EMA, and ICH have imposed strict ...

Nitrosamines are classified as potential cancer-causing agents. The chemicals have been found in several prescription drugs in recent years, prompting recalls. Most recently, Pfizer issued a voluntary ...

Nitrosamine sind unter in Lebensmitteln, Kosmetika, Tabakerzeugnissen sowie Bedarfsgegenständen aus Gummi enthalten. (c) proplanta Unser Körper kann Nitrosamine auch selbst produzieren. Zudem können ...

The US Food and Drug Administration (FDA) has announced that it will give drugmakers more time to conduct testing for nitrosamine drug substance-related impurities (NDSRIs) in approved pharmaceuticals ...

Our FDA Compliance & Enforcement Team reviews how the Food and Drug Administration’s first guidance on nitrosamine impurities shows what the FDA has learned about the sources of such impurities and ...

Comprised of the most frequently targeted nitrosamine compounds for pharmaceutical impurities testing, Restek’s new, multicomponent Nitrosamines 7 Standard contains seven key nitrosamines in a single ...

Updates to Ph. Eur. include validated tests for N-nitrosamine impurities in sartan APIs. Vielle (EDQM): The new chapter ‘Test for bacterial endotoxins using recombinant factor C’ (2.6.32) describes a ...

As part of the ongoing safety investigation of potentially carcinogenic impurities detected in angiotensin II receptor blocker (ARB) medications, the Food and Drug Administration (FDA) has released a ...